Bifidobacterium combined with high-frequency transcranial magnetic stimulation in the treatment of adolescent depression Mental and Behavioural Disorders
Conditions
Interventions
A total of 100 patients were selected, and divided into the experimental group(n=50) and the control group(n=50) using a random number table. Patients in the experimental group were treated with Bifid
Sponsors
Wenzhou Seventh People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 13-18 years old 2. Met the diagnostic criteria for depression in the International Classification of Disease-10 (ICD-10) 3. With a total score of the Hamilton Rating Scale for Depression (HAMD-24) =20 in the initial assessment 4. Who were right-handed
Exclusion criteria
Exclusion criteria: 1. With a definite diagnosis of other mental disorders in the past 2. With a past or current history of manic episodes 3. With a past or current history of severe physical diseases 4. Who used antidepressants, mood stabilizers, steroids, anti-inflammatory drugs, antibiotics, and immunomodulators in the past 1 month 5. Who used lactic acid bacteria products for =7 days in the past 1 month 6. With a history of alcohol or psychoactive substance abuse within the last 3 months 7. With contraindications for RTMS, including but not limited to intracranial metal foreign bodies, cardiac pacemakers, and ear hearing aids 8. Complicated with organic brain diseases, epileptic diseases, and severe physical diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Depression symptoms measured using the Hamilton Rating Scale for Depression (HAMD-24) score before and after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| The following secondary outcome measures are assessed before and after treatment: 1. The levels of serum inflammatory factors and neuroendocrine indicators: serum tumor necrosis factor-a (TNF-a), interleukin-1ß (IL-1ß), IL-6, dopamine(DA), 5-hydroxytryptamine(5-HT) and cortisol(COR) were measured by ELISA using an automatic biochemical analyzer (Dxc800, Beckman, USA). 2. The relative expression levels of serum miR-16 and miR-195 were measured using PCR 3. Remission rate measured using HAMD scores (difference in scores before and after treatment/score before treatment × 100%) 4. The incidence rate of adverse reactions measured using events reporting and calculated by dividing the number of patients with adverse reactions by the total number of patients | — |
Countries
China
Contacts
Public ContactCong-Cong Chen
Outcome results
None listed